Diagnostic Performance of Circulating miR-21, Oxidative Stress Biomarkers, and Composite Inflammatory–Oxidative Stress Indices in Ulcerative Colitis

Authors

  • Ahmed Abd Temur Department of Applied Pathological Analysis, College of Science, Al-Nahrain University, Baghdad, IRAQ https://orcid.org/0009-0006-0787-8408
  • Nawar Fadhil Razooqi Department of Chemistry, College of Science, Al-Nahrain University, Baghdad 10072, IRAQ
  • Ibrahim Abdulkareem Sabri Department of Applied Pathological Analysis, College of Science, Al-Nahrain University, Baghdad, IRAQ

DOI:

https://doi.org/10.55544/sjmars.5.4.2

Keywords:

ulcerative colitis, miR-21, oxidative stress, IL-6, fecal calprotectin biomarker

Abstract

Ulcerative colitis is a colonic inflammatory disease that is long-term. Inflammatory, oxidative stress, and molecular activation biomarkers could enhance the evaluation of the disease. The circulation of the miR-21 is also relevant in mucosal inflammation and its clinical significance in ulcerative colitis is yet to be determined. This study tries to measure circulating miR-21, oxidative stress biomarkers and inflammatory indices in patients with ulcerative colitis and to test associations between them and disease activity, fecal calprotectin and composite inflammatory oxidative stress indices. This case–control study included 121 adults recruited at the Teaching Hospital for Digestive and Liver Diseases, Medical City, Baghdad, from 9 February 2025 to 23 October 2025. A total of 88 patients who had confirmed ulcerative colitis and 33 healthy controls were included in the sample. There were active disease and remission. Standard immunochemical and colorimetric measures were taken of serum CRP, IL-6, MDA, TAC and SOD. qRT-PCR was used to determine the levels of circulating miR-21. Fecal calprotectin and Mayo endoscopic subscore also were noted. Correlations, group comparisons, effect sizes, ROC analysis and exploratory regression models were carried out. Compared with controls, patients with ulcerative colitis had higher CRP, IL-6, MDA, miR-21, fecal calprotectin, IOSI, and Advanced IOSI, and lower TAC and SOD (all p < 0.001). CRP, IL-6, MDA, fecal calprotectin, IOSI, Advanced IOSI, TAC and SOD were significantly higher in active disease than remission (all p < 0.001). The level of circulating miR-21 was higher in comparison to controls but lower in active disease than in remission (p = 0.026). There was a strong correlation between IOSI and Advanced IOSI and fecal calprotectin. There was very high discrimination of a number of markers in these results set using ROC including CRP, IL-6, fecal calprotectin, IOSI and Advanced IOSI. The results indicate that there is a strong association between ulcerative colitis, systemic inflammation and oxidative imbalance. It seems that circulating miR-21 can be relevant, yet its activity can vary in response to activity states, and be altered by treatment. Composite inflammatory-oxidative stress indexes were well-performing and potentially provide a convenient summary of multi-marker perturbation. Clinical adoption still needs to be externally validated.

References

[1] Adams, S. M., Bornemann, P. H., & Ulbrych, T. M. (2022). Ulcerative colitis: Rapid evidence review. American Family Physician, 105(4), 406–411.

[2] Alamdari-Palangi, V., Vahedi, F., Shabaninejad, Z., Dokeneheifard, S., Movehedpour, A., Taheri-Anganeh, M., & Savardashtaki, A. (2021). microRNA in inflammatory bowel disease at a glance. European Journal of Gastroenterology & Hepatology, 32(2), 140–148. https://doi.org/10.1097/MEG.0000000000001815

[3] Amiriani, T., Farnia, P., Ali-Asgari, A., Soltani-Arabshahi, K., Afshar, M., & Amari, A. (2018). Assessing the correlation of fecal calprotectin and the clinical disease activity index in patients with ulcerative colitis. Gastroenterology Nursing, 41(3), 201–205. https://doi.org/10.1097/SGA.0000000000000314

[4] Baumgart, D. C., & Carding, S. R. (2007). Inflammatory bowel disease: Cause and immunobiology. Lancet, 369(9573), 1627–1640. https://doi.org/10.1016/S0140-6736(07)60750-8

[5] Burisch, J., & Munkholm, P. (2013). Inflammatory bowel disease epidemiology. Current Opinion in Gastroenterology, 29(4), 357–362. https://doi.org/10.1097/MOG.0b013e32836229fb

[6] Dotan, I., & Mayer, L. (2002). Immunopathogenesis of inflammatory bowel disease. Current Opinion in Gastroenterology, 18(4), 421–427. https://doi.org/10.1097/00001574-200207000-00005

[7] Dusunceli, I., Gok Sargin, Z., Celik, U., & Sargin, F. (2025). The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis. Biomarkers in Medicine, 19(4), 113–119. https://doi.org/10.1080/17520363.2025.2459596

[8] Fries, W., & Comunale, S. (2011). Ulcerative colitis: Pathogenesis. Current Drug Targets, 12(10), 1373–1382. https://doi.org/10.2174/138945011796818261

[9] Holtkamp, W., Stollberg, T., Reis, H. E., & Brand, K. (1995). Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. Journal of Clinical Gastroenterology, 20(2), 123–126. https://doi.org/10.1097/00004836-199503000-00010

[10] Hu, Y., Huang, X., Mei, Y., Wang, Y., Yang, Y., & Zhou, Y. (2023). Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin versus fecal immunochemical test: A systematic review and meta-analysis. Turkish Journal of Gastroenterology, 34(9), 892–901. https://doi.org/10.5152/tjg.2023.22812

[11] Ke, Y., Liu, X., Niu, T., Qiang, Z., & Gao, F. (2024). MIR-21 regulating distribution of intestinal flora through TNF-α promotes progression of ulcerative colitis. Journal of Medical Biochemistry, 43(2), 299–305. https://doi.org/10.5937/jomb0-43320

[12] Krzystek-Korpacka, M., Kempiński, R., Bromke, M., Neubauer, K., & Żurek, M. (2020). Oxidative stress markers in inflammatory bowel diseases: Systematic review. Diagnostics, 10(8), Article 601. https://doi.org/10.3390/diagnostics10080601

[13] Loftus, E. V., Jr. (2004). Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 126(6), 1504–1517. https://doi.org/10.1053/j.gastro.2004.01.063

[14] Lu, X., Wu, F., Jiang, M., Sun, X., Tian, G., Wang, J., & Zheng, D. (2020). The role of the miR-21-5p-mediated inflammatory pathway in ulcerative colitis. Experimental and Therapeutic Medicine, 19(2), 981–989. https://doi.org/10.3892/etm.2019.8277

[15] Mak, W. Y., Zhao, M., Ng, S. C., & Burisch, J. (2020). The epidemiology of inflammatory bowel disease: East meets West. Journal of Gastroenterology and Hepatology, 35(3), 380–389. https://doi.org/10.1111/jgh.14872

[16] Mazlam, M. Z., & Hodgson, H. J. F. (1994). Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut, 35(1), 77–83. https://doi.org/10.1136/gut.35.1.77

[17] Menéndez, S., Reigada, D., Martínez-Augustin, O., de la Oliva, J., Ballester, I., & Sánchez de Medina, F. (2013). Serum microRNA-21 usefulness in the inflammatory pathology of the colon. Revista de Gastroenterología de México, 78(2), 70–74. https://doi.org/10.1016/j.rgmx.2013.02.004

[18] Mosli, M. H., Alawadhi, S., & Hasan, F. (2021). Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: A systematic review and meta-analysis. Inflammatory Intestinal Diseases, 6(3), 1–9. https://doi.org/10.1159/000518003

[19] Park, J., & Cheon, J. H. (2021). Incidence and prevalence of inflammatory bowel disease across Asia. Yonsei Medical Journal, 62(2), 99–108. https://doi.org/10.3349/ymj.2021.62.2.99

[20] Piechota-Polanczyk, A., & Fichna, J. (2014). Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn-Schmiedeberg's Archives of Pharmacology, 387(7), 605–620. https://doi.org/10.1007/s00210-014-0985-1

[21] Raab, Y., Gerdin, B., Ahlstedt, S., & Hällgren, R. (1994). Enhanced intestinal synthesis of interleukin-6 is related to disease severity and activity in ulcerative colitis. Digestion, 55(1), 44–49. https://doi.org/10.1159/000201122

[22] Shayesteh, A. A., Daryani, N. E., Sharifian, A., Haghpanah, B., Zali, M. R., & Shahraz, S. (2013). Epidemiological, demographic, and colonic extension of ulcerative colitis in Iran: A systematic review. Middle East Journal of Digestive Diseases, 5(1), 29–36.

[23] Tüzün, A., Erdil, A., Inal, V., Aydin, A., Bağci, S., Yeşilova, Z., Sayal, A., Karaeren, N., & Dağalp, K. (2002). Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clinical Biochemistry, 35(7), 569–572. https://doi.org/10.1016/S0009-9120(02)00361-2

[24] Zamani, F., Mohamadnejad, M., Shakeri, R., Amiri, A., Najafi, S., Alimohamadi, S. M., & Malekzadeh, R. (2013). Diagnostic value of fecal calprotectin in patients with ulcerative colitis. Middle East Journal of Digestive Diseases, 5(2), 76–80.

Downloads

Published

2026-08-03

How to Cite

Temur, A. A., Razooqi, N. F., & Sabri, I. A. (2026). Diagnostic Performance of Circulating miR-21, Oxidative Stress Biomarkers, and Composite Inflammatory–Oxidative Stress Indices in Ulcerative Colitis. Stallion Journal for Multidisciplinary Associated Research Studies, 5(4), 10–18. https://doi.org/10.55544/sjmars.5.4.2

Issue

Vol. 5 No. 4 (2026): August Issue

Section

Articles

License

Copyright (c) 2026 Stallion Journal for Multidisciplinary Associated Research Studies

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.